Citations

Clear

6 citation(s) found for "Section, Thyroid".

Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus
Giovanella, Luca , Görges, Rainer, Ovčariček, Petra Petranović , Tuttle, R. Michael , Verburg, Frederik A. , Group, hsTg&TgAb Consensus Working, Borowczyk, Martyna , Chiovato, Luca , Section, Thyroid, Knappe, Luisa, Magri, Flavia , Rimmele, Harald, Giovanella, Luca , D’Aurizio, Federica , Algeciras‐Schimnich, Alicia , Visser, W. Edward , Group, hsTg&TgAb Consensus Working, Duntas, Leonidas H. , Feldt-Rasmussen, Ulla , Leenhardt, Laurence , Seregni, Ettore Cesare

Mayo Clinic

European Journal of Endocrinology | August 25, 2023 | Volume: 189 | Issue: 2 | Pages: R11-R27

10.1093/ejendo/lvad109 | PMID 37625447 Get It

AbstractObjectiveThyroglobulin measurement is the cornerstone of modern management of differentiated thyroid cancer, with clinical decisions on treatment and follow-up based on the results of such measurements. However, numerous factors need to be considered regarding measurement with and interpretation of thyroglobulin assay results.DesignThe present document provides an integrated update to the 2013 and 2014 separate clinical position papers of our group on these issues.MethodsIssues concerning analytical and clinical aspects of highly-sensitive thyroglobulin measurement will be reviewed and discussed based on an extensive analysis of the available literature.ResultsThyroglobulin measurement remains a highly complex process with many pitfalls and major sources of interference, especially anti-thyroglobulin antibodies, need to be assessed, considered and, when necessary, dealt with appropriately.ConclusionsOur expert consensus group formulated 53 practical, graded recommendations for guidance on highly-sensitive thyroglobulin and TgAb in laboratory and clinical practice, especially valuable where current guidelines do not offer sufficient guidance.
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
Shonka, David C. , Geiger, J.L. , Park, Jong Chul , Jasim, Sina , Ahmed, Amr H. Abdelhamid , Bible, Keith C. , Brose, Marcia S. , Dabekaussen, Kirsten F. A. A. , Dias‐Santagata, Dora , Ghossein, Ronald , Gopal, Raj K., Ryder, Mabel , Sherman, Eric J. , Shin, Jennifer J. , Stack, Brendan C. , Tuttle, R. Michael , Wirth, Lori J. , Zafereo, Mark , Park, Jong C , Abdelhamid Ahmed, Amr H , Cabanillas, Maria E , Davies, Louise , Ryder, Mabel M, Ryder, Mabel , Ho, Alan L. , Chintakuntlawar, Ashish V. , Seetharamu, Nagashree , Cabanillas, Maria E. , Fagin, James A. , Faquin, William C , Miyauchi, Akira , Nikiforov, Yuri E. , Ringel, Matthew D. , Robinson, Bruce , Sadow, Peter M. , Randolph, Gregory William

Mayo Clinic

Head & Neck | March 11, 2022 | Volume: 44 | Issue: 6 | Pages: 1277-1300

10.1002/hed.27025 | PMID 35274388 Get It

AbstractBackgroundThe development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence‐based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.MethodsAn expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.ResultsA review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.ConclusionsWith the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS‐ES) on Pediatric Benign and Malignant Thyroid Surgery
Stack, Brendan C. , Twining, Christine, Rastatter, Jeff C., Diercks, Gillian R. , Kazahaya, Ken , Rivkees, Scott A. , Sheyn, Tony, Shin, Jennifer J. , Smith, Jessica R. , Thompson, Geoffrey B. , Viswanathan, Pushpa, Brooks, Jennifer A. , Angelos, Peter , Baloch, Zubair , Faquin, William C , Wassner, Ari J , Randolph, Gregory William

Mayo Clinic

Head & Neck | January 2, 2021 | Volume: 43 | Issue: 4 | Pages: 1027-1042

10.1002/hed.26586 | PMID 33386657 Get It

AbstractObjectivesTo provide a clinical disease state review of recent relevant literature and to generate expert consensus statements regarding the breadth of pediatric thyroid cancer diagnosis and care, with an emphasis on thyroid surgery. To generate expert statements to educate pediatric practitioners on the state‐of‐the‐art practices and the value of surgical experience in the management of this unusual and challenging disease in children.MethodsA literature search was conducted and statements were constructed and subjected to a modified Delphi process to measure the consensus of the expert author panel. The wording of statements, voting tabulation, and statistical analysis were overseen by a Delphi expert (J.J.S.).ResultsTwenty‐five consensus statements were created and subjected to a modified Delphi analysis to measure the strength of consensus of the expert author panel. All statements reached a level of consensus, and the majority of statements reached the highest level of consensus.ConclusionPediatric thyroid cancer has many unique nuances, such as bulky cervical adenopathy on presentation, an increased incidence of diffuse sclerosing variant, and a longer potential lifespan to endure potential complications from treatment. Complications can be a burden to parents and patients alike. We suggest that optimal outcomes and decreased morbidity will come from the use of advanced imaging, diagnostic testing, and neural monitoring of patients treated at high‐volume centers by high‐volume surgeons.
Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophtha
Singer, Michael C. , Marchal, Francis, Bernet, Vic, Boucai, Laura , Buchholzer, Samanta , Burkey, Brian B., Eisele, David W. , Faure, Fréderic , Freitag, Suzanne K. , Gillespie, M. Boyd , Harrell, R. Mack, Hartl, Dana M. , Haymart, Megan R. , Leffert, Jonathan, Mandel, Susan J., Miller, Barbra S. , Pearce, Elizabeth N. , Rahmati, Rahmatullah, Ryan, William R. , Schaitkin, Barry M., Schlumberger, Martin, Stack, Brendan C. , Nostrand, Doug Van, Wong, Ka Kit , Stack, Brendan C , Pearce, Elizabeth N , Angelos, Peter , Bernet, Victor , Buchholzer, Samanta , Erkul, Evren , Morris, John, Nostrand, Douglas Van , Randolph, Gregory William

Mayo Clinic

Head & Neck | August 26, 2020 | Volume: 42 | Issue: 11 | Pages: 3446-3459

10.1002/hed.26417 | PMID 32812307 Get It

AbstractBackgroundPostoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.MethodsA multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.ResultsConsensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.ConclusionSalivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules
Meltzer, Charles , Irish, Jonathan C. , Busaidy, Naifa L. , Dwojak, Sunshine , Haugen, Bryan R. , Harrell, R. Mack, Haymart, Megan R. , McIver, Bryan, Monteiro, Eric, Odell, Michael , Scharpf, Joseph , Shaha, Ashok R. , Shin, Jennifer J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Urken, Mark L. , Wiseman, Sam M. , Meltzer, Charles J , Angelos, Peter , Davies, Louise , Ferris, Robert L. , Mechanick, Jeffrey I. , Morris, John C., Morris, Luc G T , Shonka, David C. , Wong, Richard J. , Randolph, Gregory William

Mayo Clinic

Head & Neck | December 18, 2018 | Volume: 41 | Issue: 4 | Pages: 843-856

10.1002/hed.25526 | PMID 30561068 Get It

AbstractBackgroundCare for patients with thyroid nodules is complex and multidisciplinary, and research demonstrates variation in care. The objective was to develop clinical guidelines and quality metrics to reduce unwarranted variation and improve quality.MethodsMultidisciplinary expert consensus and modified Delphi approach. Source documents were workflow algorithms from Kaiser Permanente Northern California and Cancer Care of Ontario based on the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.ResultsA consensus‐based, unified preoperative, perioperative, and postoperative workflow was developed for North American use. Twenty‐one panelists achieved consensus on 16 statements about workflow‐embedded process and outcomes metrics addressing safety, access, appropriateness, efficiency, effectiveness, and patient centeredness of care.ConclusionA panel of Canadian and United States experts achieved consensus on workflows and quality metric statements to help reduce unwarranted variation in care, improving overall quality of care for patients diagnosed with thyroid nodules.
AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State‐of‐the‐art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features
Nikiforov, Yuri E. , Terris, Davis, Seethala, Raja R. , Sabra, Mona M. , McIver, Bryan, Bernet, Victor , Harrell, R. Mack, Busaidy, Naifa L. , Sadow, Peter M. , Shindo, Maisie L., Nikiforov, Yuri , Terris, Davis , Bernet, Victor J, Ferris, Robert L. , Ridge, John Andrew , Angelos, Peter , Duh, Quan‐Yang , Wong, Richard J. , Fagin, James A. , Cibas, Edmund S. , Faquin, William C , Baloch, Zubair , Orloff, Lisa A. , Davies, Louise , Randolph, Gregory William

Mayo Clinic

Head & Neck | June 27, 2018 | Volume: 40 | Issue: 9 | Pages: 1881-1888

10.1002/hed.25141 | PMID 29947030 Get It

AbstractThe newly introduced pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) will result in less bilateral thyroid surgery as well as deescalation in T4 suppressive and radioactive iodine treatment. Although, NIFTP is a nonmalignant lesion that has nuclear features of some papillary malignancies, the challenge for the surgeon is to identify a lesion as possibly NIFTP before the pathologic diagnosis. NIFTP, due to its reduction of overall rates of malignancy, will result in the initial surgical pendulum swinging toward lobectomy instead of initial total thyroidectomy. This American Head and Neck Society endocrine section consensus statement is intended to inform preoperative evaluation to attempt to identify those patients whose final pathology report may ultimately harbor NIFTP and can be offered a conservative surgical plan to assist in cost‐effective, optimal management of patients with NIFTP.